Apollo Endosurgery, Inc.
APEN · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.55 | -0.64 | -0.15 | 0.32 |
| FCF Yield | -3.59% | -3.25% | -4.50% | -3.85% |
| EV / EBITDA | -69.22 | -22.70 | -14.99 | -33.83 |
| Quality | ||||
| ROIC | -8.63% | -6.38% | -6.30% | -6.64% |
| Gross Margin | 53.28% | 54.86% | 56.76% | 56.25% |
| Cash Conversion Ratio | 1.08 | 0.54 | 0.58 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.27% | 20.31% | 20.03% | 10.91% |
| Free Cash Flow Growth | -47.71% | -10.44% | 28.25% | -91.15% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | 1.37 | 2.48 | 4.47 |
| Interest Coverage | -7.08 | -5.45 | -5.45 | -5.93 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.53 | 0.57 | 0.55 |
| Cash Conversion Cycle | 161.16 | 160.42 | 139.81 | 144.41 |